Last reviewed · How we verify

Administration of Azithromycin on Day 1

London School of Hygiene and Tropical Medicine · FDA-approved active Small molecule

Administration of Azithromycin on Day 1 is a Macrolide antibiotic Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently FDA-approved for Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections), Atypical infections (Mycoplasma, Chlamydia, Legionella).

Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections), Atypical infections (Mycoplasma, Chlamydia, Legionella).

At a glance

Generic nameAdministration of Azithromycin on Day 1
SponsorLondon School of Hygiene and Tropical Medicine
Drug classMacrolide antibiotic
TargetBacterial 50S ribosomal subunit
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Azithromycin binds to the bacterial 50S ribosomal subunit and inhibits transpeptidation and translocation, thereby preventing peptide bond formation and halting protein synthesis. This bacteriostatic action is effective against a broad spectrum of gram-positive and gram-negative bacteria, as well as atypical organisms. The drug accumulates in tissues and has a long half-life, allowing for convenient dosing schedules.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Administration of Azithromycin on Day 1

What is Administration of Azithromycin on Day 1?

Administration of Azithromycin on Day 1 is a Macrolide antibiotic drug developed by London School of Hygiene and Tropical Medicine, indicated for Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections), Atypical infections (Mycoplasma, Chlamydia, Legionella).

How does Administration of Azithromycin on Day 1 work?

Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.

What is Administration of Azithromycin on Day 1 used for?

Administration of Azithromycin on Day 1 is indicated for Bacterial infections (respiratory tract, skin and soft tissue, sexually transmitted infections), Atypical infections (Mycoplasma, Chlamydia, Legionella).

Who makes Administration of Azithromycin on Day 1?

Administration of Azithromycin on Day 1 is developed and marketed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is Administration of Azithromycin on Day 1 in?

Administration of Azithromycin on Day 1 belongs to the Macrolide antibiotic class. See all Macrolide antibiotic drugs at /class/macrolide-antibiotic.

What development phase is Administration of Azithromycin on Day 1 in?

Administration of Azithromycin on Day 1 is FDA-approved (marketed).

What are the side effects of Administration of Azithromycin on Day 1?

Common side effects of Administration of Azithromycin on Day 1 include Gastrointestinal disturbance (nausea, diarrhea, abdominal pain), Headache, Vaginitis, QT prolongation, Hepatotoxicity.

What does Administration of Azithromycin on Day 1 target?

Administration of Azithromycin on Day 1 targets Bacterial 50S ribosomal subunit and is a Macrolide antibiotic.

Related